Which manufacturers are producing zotuximab/veluoyin?

Zolbetuximab (zolbetuximab)-Vyloy is a monoclonal antibody targeting CLDN18.2 (tight junction protein 18.2), which is used to treat patients with certain gastric cancers and gastroesophageal junction cancers. This type of antibody drug activates the body's immune system to kill tumor cells by selectively recognizing CLDN18.2 on the surface of tumor cells. It is an important part of modern tumor immunotherapy. As an original drug, zotuximab was developed by a research and development company and approved by relevant national drug regulatory authorities. It is currently on the international market for the treatment of patients with specific indications.

Up to now, the zotuximab market is still dominated by original drugs, and there are no officially approved biosimilars or generic products. This means that all clinically used zotuximab comes from the original manufacturer, ensuring a high degree of consistency in drug ingredients, preparation technology and clinical efficacy. In overseas markets, the European and American versions of zotuximab are directly supplied by R&D companies and are produced and quality controlled in strict accordance with internationalGMP standards to ensure that the purity, stability and safety of each batch of drugs meet regulatory requirements. Since the drug is still under patent protection, other pharmaceutical companies are temporarily unable to produce generic drugs, which also gives the original drug an exclusive supply position in the market.

In clinical use, zotuximab is usually used in combination with chemotherapy regimens. Doctors will consider the patient's indications, weight, treatment cycle, and potential side effects when selecting the drug. Due to the lack of generic drugs in the current market, patients need to purchase zotuximab through formal channels to ensure that the source of the drug is legal and reliable to avoid adverse reactions and uncertainty in efficacy. At the same time, R&D companies are also actively promoting global clinical research and registration applications to expand the application of drugs in more regions and indications, which may increase the flexibility of market supply in the future.

Reference materials:https://www.astellas.com/en/news/29401